Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
OSL
vs
S
S&P/ASX 300
OSL
Over the past 12 months, OSL has underperformed S&P/ASX 300, delivering a return of -43% compared to S&P/ASX 300's 0% drop.
Stocks Performance
OSL vs S&P/ASX 300
Performance Gap
OSL vs S&P/ASX 300
Performance By Year
OSL vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Oncosil Medical Ltd
Glance View
Oncosil Medical makes a cancer treatment device used by doctors to deliver tiny radioactive particles directly into tumors, mainly for pancreatic cancer and some nearby biliary cancers. Its product is placed through a standard medical procedure and is designed to target the tumor from inside the body rather than through whole-body radiation. The company sells its treatment to hospitals and specialist cancer physicians, usually through healthcare distribution and clinical adoption pathways. Its money comes from selling the device and related treatment-use supply, with future demand tied to how widely doctors adopt the procedure and how many eligible patients are treated. What makes Oncosil different is that it sits at the intersection of medical devices and cancer therapy. It is not a drug company and not a broad hospital supplier; it is focused on one targeted therapy that aims to fit into existing interventional oncology workflows, where doctors already use imaging and endoscopy to reach hard-to-treat tumors.